Alert system helps clinicians monitor adherence to rhGH treatment

Poor adherence to recombinant human growth hormone (rhGH) can lead to patients with growth hormone deficiency (GHD) not achieving their full height potential. Researchers developed a data-driven clinical decision support system for adherence risk management of patients with GHD treated with rhGH.

The system is based on “traffic light” visualizations and generates 3 clusters—green representing high adherence, yellow representing medium adherence, or red representing low adherence.

For the daily adherence-based traffic lights, optimum thresholds were >0.82 for high adherence, 0.53-0.82 for medium adherence, and <0.53 for low adherence.

For the hours to next injection-based traffic lights, optimum thresholds were <27.18 for high adherence, 27.18-34.01 for medium adherence, and >34.01 for low adherence.

The researchers concluded that utilizing this data-driven alert system could potentially help healthcare providers monitor “sub-optimally-adherent patients to rhGH treatment for early intervention to improve treatment outcomes.”

Reference
Araújo M, van Dommelen P, Srivastava J, et al. A Data-Driven Intervention Framework for Improving Adherence to Growth Hormone Therapy Based on Clustering Analysis and Traffic Light Alerting Systems. Stud Health Technol Inform. 2021;287:23-27. doi: 10.3233/SHTI210803. PMID: 34795072.